<DOC>
	<DOCNO>NCT00904787</DOCNO>
	<brief_summary>To define maximum tolerate dose oral daily ENMD 2076 patient relapse refractory hematological malignancy</brief_summary>
	<brief_title>Study ENMD-2076 Patients With Relapsed Refractory Hematological Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Patients must relapsed/refractory hematological malignancy standard therapy anticipate result durable remission . Patients poorrisk myelodysplasia ( MDS ) [ i.e. , IPSS ≥ 1.5 ] chronic myelomonocytic leukemia ( CMML ) also candidate protocol . Relapsed/refractory leukemias include acute non lymphocytic leukemia ( AML ) WHO classification , acute lymphocytic leukemia ( ALL ) , chronic lymphocytic leukemia ( CLL ) , chronic myelogenous leukemia ( CML ) blast crisis . Patients agnogenic myeloid metaplasia ( AMM ) also eligible . Patients relapse refractory lymphoma myeloma may also participate . Age ≥18 year . Adequate performance status Interval prior treatment time study drug administration least 2 week cytotoxic agent , least 5 halflives noncytotoxic agent adequate recovery prior toxicity . If patient transplant , least 6 month must pass initiation treatment protocol stable graft versus host disease ( change severity ) 4 week precede study entry ( applicable ) . Persistent clinically significant chronic toxicity prior therapy must resolve baseline NCI CTCAE Grade &lt; 1 Adequate laboratory result within 10 day ENMD2076 administration ( unless abnormality consider attributable leukemia ) Pregnant breastfeed woman . Clinical evidence bowel obstruction , active uncontrolled malabsorption syndrome history total gastrectomy . Impaired cardiac function include myocardial infarction within previous 3 month , symptomatic coronary artery disease , arrhythmias control medication , uncontrolled hypertension , uncontrolled congestive heart failure . Blood pressure must &lt; 150/90 time enrollment . Receiving treatment disease QTc prolongation define ≥ 470 m .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Hematologic neoplasm</keyword>
</DOC>